WuXi AppTec

AboutJob opportunities

WuXi AppTec’s Laboratory Testing Division is a comprehensive and integrated testing platform for drug and medical device development. Fully integrated within WuXi AppTec, a world-class CRO with operations in China and the US, the Laboratory Testing Division provides in vivo and in vitro assays from early screening through clinical sample analysis and medical device testing from development through product life cycle management. We operate with full transparency, providing the high-quality data you need to advance your project while meeting international standards for regulatory compliance and maintaining industry-leading turnaround times. The Laboratory Testing Division consists of three integrated testing platforms including WuXi AppTec IND (WIND) for preclinical drug development, clinical drug development, and medical device testing. Each platform is supported by the complementary capabilities of our four service

 

As a global company with operations across Asia, Europe and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,600 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”